AOD-9604 Dosage Guide: Fat Loss Protocols, Timing, and Stacking

AOD-9604 Dosage Guide: Fat Loss Protocols, Timing, and Stacking

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH amino acids 177–191). It was developed by Monash University researchers in Australia specifically to isolate and leverage hGH's fat-burning properties while eliminating the side effects — particularly elevated blood glucose and IGF-1-mediated growth effects — associated with full-length HGH.

AOD-9604 remains one of the most targeted peptides for fat metabolism and is notable for its exceptional safety profile and FDA GRAS (Generally Recognized As Safe) designation for use in functional foods — a distinction no other peptide on this list holds.

How AOD-9604 Works

AOD-9604 exerts its lipolytic (fat-burning) effects through several mechanisms:

• Mimics the lipolytic domain of HGH: The C-terminal fragment (177–191) contains the region responsible for activating lipolysis in adipocytes (fat cells)
• Activates beta-3 adrenergic receptors: Stimulates fat cell receptors that trigger fat breakdown
• Inhibits lipogenesis: Suppresses the formation of new fat from carbohydrates
• Stimulates fat oxidation: Increases the rate at which fat is used as fuel
• No effect on IGF-1: Unlike full HGH, AOD-9604 does not stimulate IGF-1 production — it is purely lipolytic
• No effect on blood glucose: Does not cause the insulin resistance associated with HGH

Research in human trials confirmed that AOD-9604 reduced body weight in obese patients without altering glucose, insulin, or lipid levels — a profile that makes it uniquely safe among GH-derived compounds.

Standard AOD-9604 Dosage

The most widely studied and used dose is 300 mcg per day.

Standard protocol:

• 300 mcg per day, injected subcutaneously
• Administered once daily in a fasted state

Conservative starting dose:

• 150–200 mcg per day (first 1–2 weeks to assess tolerance)

Higher dose protocols (limited evidence):

• 500–600 mcg per day (some practitioners use this for accelerated protocols, though clinical trials used 300 mcg)

The pivotal human clinical trials conducted by Metabolic Pharmaceuticals (the company that developed AOD-9604) used 1 mg/day (1,000 mcg) in some arms, but 300 mcg daily was identified as the optimal dose balancing efficacy and safety. Doses above 1 mg showed no additional benefit in these trials.

Fasted State Administration

Fasted administration is critical for AOD-9604 and is one of the most consistently emphasized aspects of its use:

Why fasting matters:

• Elevated insulin from meals directly inhibits lipolysis in adipocytes — AOD-9604's primary target
• A fasted state with low circulating insulin allows AOD-9604 to activate beta-3 adrenergic pathways without competition
• Fat oxidation rates are naturally elevated in the fasted state, and AOD-9604 amplifies this

Optimal fasting windows for injection:

1. Morning fasted (preferred): Inject upon waking after an overnight fast (8–12 hours fasted)
2. Between meals: Inject during an extended fasting period, at least 2–3 hours after the last meal

Post-injection: Wait 20–30 minutes before eating after the morning injection to allow the lipolytic effect to occur.

Injection Site: Subcutaneous Abdomen

For fat loss applications, subcutaneous injection into the abdominal region is the preferred site:

Rationale: Visceral and abdominal subcutaneous fat depots are the primary targets of AOD-9604's lipolytic activity. Local subcutaneous injection near these fat depots may enhance local concentration effects, though AOD-9604 also has systemic distribution.

Injection technique:

• Pinch a fold of abdominal skin 1–2 inches from the navel
• 27–30 gauge insulin syringe, 0.5 inch needle
• Insert at a 45-degree angle
• Inject slowly and remove needle
• Apply gentle pressure to injection site

Alternative sites: Thigh, upper arm — all are acceptable and can be rotated to prevent lipohypertrophy at the abdomen.

12-Week Protocol

AOD-9604 protocols are typically structured around 12 weeks:

Weeks 1–2 (acclimation):

• 150 mcg/day, fasted morning injection
• Purpose: Assess tolerance, establish injection routine

Weeks 3–12 (full protocol):

• 300 mcg/day, fasted morning injection
• Continue daily throughout

Post-cycle:

• 4–6 weeks off before repeating
• Assess fat loss progress; adjust nutrition and training

Total duration considerations: The clinical trials ran for 12 weeks. There is no strong evidence for diminishing returns within a 12-week cycle, but taking a break between cycles is practical for assessing progress.

AOD-9604 and Carbohydrate Intake

An important dietary consideration: AOD-9604 inhibits lipogenesis (conversion of carbohydrates to fat). This means its effects may be most potent in the context of reduced carbohydrate intake, where the body is already relying more heavily on fat for fuel.

Most effective dietary contexts:

• Low-carbohydrate diet (under 100g carbs/day)
• Intermittent fasting protocols
• Caloric deficit

AOD-9604 is not a substitute for dietary management — it amplifies the lipolytic response but does not overcome a caloric surplus. Users who combine AOD-9604 with caloric optimization, adequate protein, and resistance training report the most significant fat loss results.

Stacking AOD-9604 with CJC-1295

AOD-9604 is frequently stacked with CJC-1295 without DAC (and ipamorelin) for enhanced body recomposition:

Rationale:

• AOD-9604: Directly targets fat cells for lipolysis; no IGF-1 elevation
• CJC-1295 no-DAC + Ipamorelin: Raises GH/IGF-1 for muscle protein synthesis, recovery, and additional lipolysis

The combination theoretically addresses fat loss from two angles: direct adipocyte activation (AOD-9604) and systemic GH elevation (CJC-1295/ipamorelin). It also provides anabolic support to preserve or build lean mass while in a caloric deficit.

Combined protocol:

• Morning (fasted): AOD-9604 300 mcg SubQ
• Before bed (fasted): CJC-1295 no-DAC 100 mcg + Ipamorelin 200 mcg SubQ (combined in one syringe)
• Duration: 12 weeks

Since AOD-9604 does not elevate IGF-1, the stack does not produce additive IGF-1 concerns — it adds targeted fat burning on top of the GH peptide stack.

Adding Tesamorelin instead: Tesamorelin is the most potent GHRH analog for visceral fat reduction. Some practitioners substitute CJC-1295 with tesamorelin in fat-loss focused protocols, though tesamorelin is significantly more expensive.

Reconstitution

AOD-9604 is sold as a lyophilized powder:

Common vial sizes: 1 mg, 2 mg, 5 mg

Reconstitution example (2 mg vial):

• Add 2 mL bacteriostatic water = 1 mg/mL
• Each 0.3 mL = 300 mcg (the standard daily dose)
• On a U-100 insulin syringe: 30 units = 300 mcg

Storage:

• Lyophilized: Refrigerate at 2–8°C; stable for 12–24 months
• Reconstituted: Refrigerate; use within 28–30 days
• Protect from light and heat; do not freeze reconstituted solution

Expected Results and Timeline

Weeks 1–4: Energy levels often improve due to enhanced fat oxidation; mild reduction in appetite reported by some users; early fat loss changes (0.5–1 lb/week in combination with caloric management)

Weeks 4–8: More noticeable body composition changes, particularly in abdominal fat stores; improved definition; continued steady fat loss

Weeks 8–12: Cumulative effect on visceral fat becomes measurable; total fat loss in clinical trials averaged 1–2 kg over 12 weeks with diet optimization

Important context: Clinical trial results in sedentary, obese subjects may underrepresent what active individuals with controlled nutrition can achieve. AOD-9604 is a tool, not a standalone solution.

Safety Profile and Side Effects

AOD-9604's safety profile is exceptionally well-characterized compared to most peptides because it has been through human clinical trials:

Phase 2 clinical trials found:

• No effect on fasting glucose or insulin resistance
• No IGF-1 elevation
• No effect on lipids or liver enzymes
• No adverse cardiovascular events
• Good tolerability across all dose groups tested (1 mg – 9 mg/day)

Reported side effects (primarily self-reported):

• Mild injection site irritation
• Occasional headache
• Mild redness at injection site

The FDA GRAS designation for use in functional foods represents a meaningful safety endorsement that few other peptides have received.

Contraindications:

• Active cancer (theoretical concern with any pro-lipolytic/pro-growth compound)
• Pregnancy
• Known hypersensitivity to GH-derived peptides

Frequently Asked Questions

Q: Does AOD-9604 affect IGF-1 levels? No. This is one of AOD-9604's most important distinctions. Unlike full HGH, AOD-9604 does not stimulate IGF-1 production or elevate circulating IGF-1 levels. This makes it suitable for individuals who want fat-loss benefits without the IGF-1-related concerns of HGH therapy.

Q: How much fat loss can I expect from AOD-9604? Human clinical trials reported an average of 1–2 kg (2.2–4.4 lbs) of fat loss over 12 weeks vs. placebo, in subjects who were not otherwise intervening with diet or exercise. With a proper caloric deficit and training program, results may be more substantial. AOD-9604 is best thought of as an accelerant rather than a primary fat loss strategy.

Q: Can I take AOD-9604 twice per day? Some practitioners use split dosing (150–300 mcg morning + 150–300 mcg afternoon, both fasted). There is no strong evidence this is superior to once-daily dosing, but it may maintain more consistent receptor activation throughout the day.

Q: Does AOD-9604 need to be cycled? Yes. Standard practice is to cycle 12 weeks on with 4–6 weeks off. There is no evidence of dependence or severe downregulation, but cycling allows for progress assessment and provides a physiological reset.

Q: Is AOD-9604 legal? AOD-9604 is not FDA-approved as a drug but holds GRAS status as a food ingredient. It is sold as a research chemical. It is prohibited by WADA in competitive sport. Regulatory status varies by country.

Q: Does AOD-9604 work for stubborn fat areas like the abdomen? Yes. Clinical data and mechanistic research specifically implicate abdominal and visceral fat as primary targets of AOD-9604's lipolytic activity. Subcutaneous injection near these areas may enhance local effects, though the evidence for targeted spot reduction even with peptides is limited.

---

This article is for informational purposes only. AOD-9604 is not FDA-approved for human therapeutic use as a drug. Consult a healthcare provider before beginning any peptide protocol.